Sherif Osman, MD
Internal Medicine · Bel Air, MDNPI 1245235852
Payments from drug & device makers
Across 55 payments — averaging $30.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$686
- Tactile Systems Technology Inc$275
- AstraZeneca$250
- Smith+Nephew$231
- Mimedx Group, Inc.$77
- Convatec Inc.$44
- plus $123 from 6 others
What the payments were for
- Food & beverage$1,685100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 25 | $686 |
| Tactile Systems Technology Inc | 6 | $275 |
| AstraZeneca | 2 | $250 |
| Smith+Nephew | 10 | $231 |
| Mimedx Group, Inc. | 4 | $77 |
| Convatec Inc. | 2 | $44 |
| Molnlycke Health Care US, LLC | 1 | $36 |
| Solventum Corporation | 1 | $29 |
| KCI USA, Inc. | 1 | $19 |
| Medela LLC | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $13 |
| Kerecis Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,685 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $27,539 |
| XareltoRivaroxaban | 17 | $22,228 |
| JardianceEmpagliflozin | 16 | $21,262 |
| SynthroidLevothyroxine Sodium | 38 | $4,644 |
| Atorvastatin Calcium | 209 | $3,190 |
| Rosuvastatin Calcium | 130 | $2,822 |
| Testosterone | 12 | $2,491 |
| Escitalopram Oxalate | 86 | $1,867 |
| Olmesartan Medoxomil | 56 | $1,658 |
| Losartan Potassium | 75 | $1,410 |
| Lisinopril | 114 | $1,210 |
| Doxycycline Hyclate | 51 | $1,200 |
| Metoprolol Succinate | 73 | $1,164 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $1,129 |
| Ezetimibe | 19 | $1,107 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bel Air
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.